Signal Management

Including signal detection, validation, prioritization, and assessment

Two men reviewing data on computer screen Two men reviewing data on computer screen

Signal Management Services

ProPharma has deep expertise across all signal detection and management activities, including validation, prioritization, and assessment using data from a wide range of sources that are relevant for signal detection for the individual product(s). We are also fully trained and experienced in the EudraVigilance Data Analysis System (EVDAS) functionality and can support MAHs to comply with their obligations for signal detection and management. We leverage our robust knowledge to select the most efficient and effective method(s) for each product that is compliant with legislative requirements.

ProPharma's simple but scalable model of signal detection and management allows clients to obtain the exact services necessary throughout the entire life cycle of their products.

Signal management is a critical process for the proactive and timely identification of potential new safety risks for medicinal products that require the utmost expertise. Signal management can be deployed throughout both the clinical development and post-marketing phases of the product lifecycle. Safety issues may affect the benefit-risk balance of the product, requiring updates to product labels and other steps that help protect patients from harm.

Signal Detection in Pharmacovigilance

Signal detection in pharmacovigilance is the systematic process of identifying and evaluating potential safety signals in the data relating to a pharmaceutical product. This process involves scrutinizing various data sources for previously unrecognized adverse events or changes in patterns of known adverse events, which might be caused by a medicine. This is vital to monitor and assure the safety of a pharmaceutical product throughout its life cycle.

Key Steps in Signal Management

  • Signal Detection: Identifying potential safety signals using various data sources such as adverse event databases, literature, and other data.

  • Signal Validation: Verifying the identified signals to ensure they are genuine and warrant further investigation.

  • Signal Confirmation: Ensuring that the identified signal is supported by robust, scientific evidence.

  • Signal Assessment: Analyzing the available data to evaluate the relationship between the medicinal product and the observed risk and providing recommendations for mitigating risk to patient safety.

  • Communication: Working with the Client to inform regulatory authorities, healthcare professionals, patients, and the public about the findings and any new safety measures or recommendations resulting from signals in the management procedure.

  • Documentation: Recording all activities, assessments, decisions, and communications for accountability and future reference.

Significance of Signal Management

Man reviewing data on a computer montior
  • Patient Safety: Ensures that any potential safety concerns with pharmaceutical products are identified and managed to safeguard patients.

  • Regulatory Compliance: Ensures that regulatory requirements for monitoring and ensuring product safety are met.

  • Informed Decision Making: Helps healthcare professionals and patients make informed decisions about medicinal products.

  • Risk-Benefit Balance: Ensures that the benefits of a pharmaceutical product continue to outweigh its risks during the entire lifecycle.

How ProPharma Overcomes Signal Management Challenges

 

  • Data Quality: Defining robust strategies to analyze available data.

  • Timely Decision Making: Ensuring that decisions and communications are made in a timely manner to protect public health.

  • Global Consistency: Globally harmonized processes to collect, process, and assess data.

Two healthcare professionals talking at a table

News & Insights

Rethinking Biometrics Resourcing in Modern Clinical Trials

May 19, 2026

Rethinking Biometrics Resourcing in Modern Clinical Trials

Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.

The Hidden Value of Medical Information: Strengthening Brand Trust

May 18, 2026

The Hidden Value of Medical Information: Strengthening Brand Trust

Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Rethinking Biometrics Resourcing in Modern Clinical Trials

May 19, 2026

Rethinking Biometrics Resourcing in Modern Clinical Trials

Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.

The Hidden Value of Medical Information: Strengthening Brand Trust

May 18, 2026

The Hidden Value of Medical Information: Strengthening Brand Trust

Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Case Study Reestablishing FDA Alignment After a CMC Disruption: A Strategic Path to BLA Approval

May 20, 2026

From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...

Case Study Response to Regulatory Request with Subsequent Full Signal Assessment

May 15, 2026

Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...

Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow